Ganaxolone Safety Profile in CDKL5 Deficiency Disorder: Results From a Phase 3 Randomized, Double-blind, Placebo-Controlled Trial

被引：0
|
作者：
Pestana-Knight, E.
Rybak, E.
Grachev, I
Miller, I
机构：
来源：
ANNALS OF NEUROLOGY | 2021年 / 90卷
关键词：
Epilepsy;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
244
引用
收藏
页码：S132 / S133
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial
    Knight, Elia M. Pestana
    Amin, Sam
    Bahi-Buisson, Nadia
    Benke, Tim A.
    Cross, J. Helen
    Demarest, Scott T.
    Olson, Heather E.
    Specchio, Nicola
    Fleming, Thomas R.
    Aimetti, Alex A.
    Gasior, Maciej
    Devinsky, Orrin
    LANCET NEUROLOGY, 2022, 21 (05): : 417 - 427
  • [2] Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial
    Downs, J.
    Jacoby, P.
    Specchio, N.
    Cross, H.
    Amin, S.
    Bahi-Buisson, N.
    Rajaraman, R.
    Suter, B.
    Devinsky, O.
    Aimetti, A.
    Busse, G.
    Olson, H. E.
    Demarest, S.
    Benke, T. A.
    Pestana-Knight, E.
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2024, 51 : 140 - 146
  • [3] Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial (vol 21, pg 417, 2022)
    Knight, Pestana E. M.
    Amin, S.
    Bahi-Buisson, N.
    LANCET NEUROLOGY, 2022, 21 (07): : E7 - E7
  • [4] Ganaxolone significantly reduces major motor seizures associated with Cdkl5 Deficiency disorder: A randomized, double-blind, placebo-controlled Phase 3 study
    Pestana--Knight, E.
    Amin, S.
    Benke, T.
    Cross, H.
    Olson, H.
    Fleming, T.
    Demarest, S.
    Specchio, N.
    EPILEPSIA, 2022, 63 : 237 - 238
  • [5] Ganaxolone significantly reduces major motor seizures in CDKL5 deficiency disorder: A randomized, DB, placebo-controlled phase 3 study
    Specchio, Nicola
    Pestana-Knight, Elia
    Amin, Sam
    Benke, Tim
    Cross, J. Helen
    Olson, Heather
    Fleming, Thomas
    Demarest, Scott
    EPILEPSIA, 2021, 62 : 288 - 288
  • [6] Ganaxolone, an Investigational Neurosteroid Treatment for Children with CDKL5 Deficiency Disorder: Results from a Phase 2 Trial
    Rogawski, Michael
    Masuoka, Lorianne
    Specchio, Nicola
    Chez, Michael
    Tarquinio, Daniel
    Lappalainen, Jaakko
    Tsai, Julia
    NEUROTHERAPEUTICS, 2018, 15 (03) : 826 - 827
  • [7] Results of a randomized, double-blind, placebo-controlled trial of lorcaserin in cocaine use disorder
    McCann, David J.
    Chen, Hegang H.
    Devine, Eric G.
    Gyaw, Shwe
    Ramey, Tatiana
    DRUG AND ALCOHOL DEPENDENCE, 2024, 255
  • [8] A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome
    Andrew Ligsay
    Anke Van Dijck
    Danh V. Nguyen
    Reymundo Lozano
    Yanjun Chen
    Erika S. Bickel
    David Hessl
    Andrea Schneider
    Kathleen Angkustsiri
    Flora Tassone
    Berten Ceulemans
    R. Frank Kooy
    Randi J. Hagerman
    Journal of Neurodevelopmental Disorders, 2017, 9
  • [9] A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome
    Ligsay, Andrew
    Van Dijck, Anke
    Nguyen, Danh V.
    Lozano, Reymundo
    Chen, Yanjun
    Bickel, Erika S.
    Hessl, David
    Schneider, Andrea
    Angkustsiri, Kathleen
    Tassone, Flora
    Ceulemans, Berten
    Kooy, R. Frank
    Hagerman, Randi J.
    JOURNAL OF NEURODEVELOPMENTAL DISORDERS, 2017, 9
  • [10] Safety and Efficacy of Intravenous Ganaxolone in Severe Postpartum Depression: Results From a Double-Blind, Placebo-Controlled Phase 2 Study
    Gutierrez-Esteinou, Rolando
    Maximos, Bassem
    Riesenberg, Robert
    Johnson, Kimball A.
    Aimetti, Alex
    Lappalainen, Jaako
    Masuoka, Lorianne
    BIOLOGICAL PSYCHIATRY, 2019, 85 (10) : S181 - S182
12345